Chimin Health Management (603222) Stock Overview

Chimin Health Management Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells human medicines and medical devices in China and internationally. The company provides non-PVC double-tube double-valve, single-tube single-valve, and single-tube double-valve soft bags; plastic bottles; and other packaging forms. It also offers medical instruments, including safety syringes, safety injection needles, sterile syringes, irrigators, dispensers, insulin syringes, infusion sets, precision filter infusion sets, and other products. In addition, the company provides in vitro diagnostics products, such as clinical chemical diagnostic, immunological diagnostic, blood testing, rapid diagnostic, and enzyme-linked immunological diagnostic reagents; laboratory instruments; and in vitro diagnostic medical products, as well as FOB fecal occult blood automatic immune monitoring and pylori Helicobacter detection kits. Further, it offers hemodialysis series products, including hemodialysis concentrate, hemodialysis tubing, and other products; and medical and health services. The company was formerly known as Zhejiang Chimin Pharmaceutical Co.,Ltd. and changed its name to Chimin Health Management Co., Ltd. in August 2018. Chimin Health Management Co., Ltd. was founded in 1996 and is based in Taizhou, China.